Georgia's life sciences sector has grown, but key ingredients still lacking

“If you're not affiliated with a university, you can't really access their labs,” said Eddie Lai, director of business development at venture capital firm Portal Innovations. “If you're trying to build your own facility, that costs a lot of money.”

By Tyler Wilkins – Staff Reporter, Atlanta Business Chronicle


This year, Shriners Children’s picked Atlanta to carry out its mission to advance pediatric care.


The Tampa-based hospital network plans to establish a research institute at Science Square, an emerging life sciences hub on the doorstep of Georgia Tech’s campus. The announcement is one of the latest wins for Georgia’s life sciences industry, which has rapidly expanded in recent years.


Economic development professionals tend to point to Georgia’s relative affordability, labor and real estate costs, net migration patterns, talent pool and academic institutions as some of the state’s attributes that have helped attract all the investment. But insufficient access to capital, shortfalls in skilled labor and other challenges have the potential to hinder innovation — limiting the industry's pace of expansion and opening a window of opportunity for rival states.


Georgia’s life sciences industry is the third-largest among Southeastern states based on the number of companies and economic impact, behind North Carolina and Florida. Despite impressive growth in recent years, the Peach State is locked in fierce competition with its neighbors. “We're seeing Tennessee creep up, and they might be able to surpass us in the next couple of years, if we don't make some significant changes,” said Maria Thacker Goethe, president and CEO of Georgia Life Sciences, an industry association formerly known as Georgia Bio.


Venture capital, federal funding drove growth in recent years

Georgia's life sciences industry began to take off after the state hosted the BIO International Convention in 2009, Thacker Goethe said. The multi-day event drew thousands of executives and other professionals to Atlanta. Hosting the event allowed state and local leaders to showcase Georgia’s strengths to the life sciences community. It caught the industry’s attention, likely helping to attract some of the big companies that have set up operations in the state. A decade later, Georgia’s life sciences industry would experience a big surge during the Covid-19 pandemic. The state captured records level of venture capital and angel investment in 2021, as well as a strong amount of National Institutes of Health funding sent to state institutions.


The region is home to approximately 18,000 life sciences jobs. Nearly 5,600 of those jobs are research and development roles, which grew by 44% from 2019 to 2022, according to a CBRE report. Georgia employed more than 78,000 people across 4,000 establishments in the

life sciences industry as of 2021, ranging from biopharma companies and medical device firms to R&D and manufacturing, according to a TEConomy report. The state added 11,000 net new jobs between 2015 and 2021, a 20% increase that outpaced the national average, according to the report. Major companies have planted operations in the state, including Takeda Pharmaceuticals, Intuitive Surgical and Alcon. Meissner Corp. is expected to create more than 1,700 jobs through a $250 million facility in Athens-Clarke County, and Boston Scientific recently expanded its presence in the state with a new research and development hub in Johns Creek.


Academic and research institutions such as Georgia Tech and Emory University have undoubtedly aided in the industry's growth. Shriners considered several locations in the Southeast for its research institute, said Leslie Stewart, the chairman of its board of trustees. It ultimately landed on Science Square to be close to Georgia Tech, with which the organization has had a longtime partnership. "Attracting new organizations [such as Shriners] creates momentum for future opportunities in recruitment and nurturing existing ecosystems," said Misti Martin, deputy commissioner of global commerce for Georgia's Department of Economic Development, in a statement. "Each new organization is a new potential partner for those already in the state or considering locating in Georgia."


Companies don’t necessarily come to Atlanta in search of moderate weather and Southern hospitality, said Katherine Lynch, a principal at Trammell Crow Co., the developer behind Science Square. “But many shared with me that they found themselves pleasantly surprised

at how much of an impact these qualities made on their ultimate decision,” Lynch said.


Georgia needs more local investors, non-university lab space

Georgia has a robust labor force with applicable skills, but its members may be working in other fields or simply not aware of the career opportunities, according to subject-matter experts.


Early-stage companies can benefit from bringing on senior talent with business know-how. But it can be difficult to persuade high-level executives to leave their jobs at a major company in another state. “In terms of venture capital in life sciences in the region, I think there's room to grow in that space,” said Kristi Brigman, chief economic development officer at the Metro Atlanta Chamber


After all, startups don’t always last. There are more opportunities to fall back on in larger markets such as Boston or San Francisco than Atlanta. For entry-level jobs, part of the problem is perception. Many people assume a graduate-level degree is needed to work in life sciences. A majority of the talent needs require a high school diploma or associate’s degree, Thacker Goethe said. Many companies provide training for those jobs, which can be high-paying and fulfilling, she said. “If you're manufacturing something that's going to help treat cancer or get the device someone needs to move and live their best life, that is very meaningful for people,” Thacker Goethe said.


The federal government provides early-stage funding to support development and commercialization through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Many states offer to match funds awarded through the programs. Georgia Research Alliance has a matching program, but it is only available to companies affiliated with member universities, Thacker Goethe said. The absence of a statewide program limits startup scaling, Thacker Goethe said. One innovator told her it was a deal-breaker in deciding where to launch his company. “He's going to set up the office in Tennessee, keep a house in Atlanta and

work remotely from Atlanta to support the company,” she said. “That’s a real problem.”


Universities play a critical role in the startup space as development and funding partners. The Trump administration's efforts to cut federal research grants could impact the ecosystem in Georgia and beyond. In the first six months of 2025, the NIH had awarded fewer grants than the previous year and had terminated or frozen funding for thousands of grants, according to a Business Journals report. “In terms of venture capital in life sciences in the region, I think there's room to grow in that space,” said Kristi Brigman, chief economic development officer at the Metro Atlanta Chamber.


There are more avenues for Atlanta startups to line up private funding than in the past. But it can still be difficult for those in life sciences to raise what they need. One of the selling points of markets such as Boston and San Francisco is the proximity to a wide array of venture capitalists. “In terms of venture capital in life sciences in the region, I think there's room to grow in that space,” said Kristi Brigman, chief economic development officer at the Metro Atlanta Chamber.


A lack of nonacademic lab space is another challenge. Tech startup founders can launch their business out of their garage if necessary. That won’t cut it for someone who needs access to lab equipment. “If you're not affiliated with a university, you can't really access their labs,” said Eddie Lai, director of business development at venture capital firm Portal Innovations' Atlanta site. “You’re stuck in the dark. If you're trying to build your own facility, that costs a lot of money.”


There have been efforts to address some of the obstacles. Consider Portal, the first tenant at Science Square Labs. The national firm

provides lab and office space to early-stage startups at a base price, with the option to pay for additional services and amenities as a company grows. Members can network with peers across the country, and they can work from other locations when they're out of town. In an effort to bolster the industry, Georgia Life Sciences is working with large employers, small companies and universities to develop a "road map." The study will produce recommendations to guide the state’s strategy around economic development, workforce pipelines and innovation investment.


'Two-edged sword': Lack of lab space was a barrier to growth but prevented a glut

Unlike Boston, Raleigh-Durham and other markets, metro Atlanta hasn’t had a physical hub centered around life sciences innovation. Academic institutions, local leaders and real estate developers are trying to create that kind of environment. In the suburbs, Gwinnett County has invested millions of dollars into Rowen. The 2,000-acre development is intended to become a major employment and research hub centered around the environment, agriculture and medicine.


Inspired by Research Triangle Park, Rowen has an ample supply of land to accommodate companies that want to establish offices and research facilities. The project is located between Athens and Atlanta, providing access to Georgia Tech, University of Georgia, Emory University and other institutions. Roads, green space, multi-use trails and other forms of infrastructure have been built in the area.


Gwinnett officials gave the green light for Rowen in the early days of the pandemic. Years later, it’s still uncertain who could become the first tenant. It took decades for North Carolina leaders to create RTP, the largest research park in the U.S. In May, Rowen Foundation President and CEO Mason Ailstock told Atlanta Business Chronicle that more than a dozen companies have considered locating at the so-called “knowledge community,” including four in just that past quarter. "We continue to make progress down that short list line for several companies today, as we compete nationally to win these huge, multimillion-dollar projects,” Ailstock said. Landing that first tenant could lead to a ripple effect, putting Rowen on the radar of other companies in expansion mode, Thacker Goethe said. “They just need one,” Thacker Goethe said. “The plan, the idea and the leadership is all in place. It’s just getting that first domino to fall.”


Trammell Crow Co. developed the first phase of Science Square with the help of Georgia Tech. The first phase includes a 13-story tower with more than 350,000 square feet of lab and office space, as well as retail and an apartment building. Shriners plans to build out its research institute in phases, with the option to take up almost half of the space in Science Square Labs, Stewart said. Earlier this year, battery manufacturer Duracell announced that it would relocate its R&D headquarters from Connecticut to two full floors at Science

Square Labs. The Georgia Department of Agriculture also leases space in the tower. Science Square is a true test of “build it and they’ll come,” said David Hartnett, former chief economic development officer at Metro Atlanta Chamber. “That is the biggest win that the life science community has had in two decades,” said Hartnett, who has held senior roles at medical device companies. “I can’t think of another deal of more importance and significance than Science Square.”


Outside of Science Square, lab-ready space available to lease is almost nonexistent in Atlanta proper, said Eric Ross, executive vice president of CBRE’s Landlord Representation Group in Atlanta and part of the leasing team for Science Square. That is a “two-edged sword” for Atlanta, Ross said. It is a challenging environment for life sciences companies across the U.S. to raise funds through private equity and venture capital, he said, resulting in leasing concerns for existing space in other markets. “From a real estate investment standpoint over the next five to 10 years, Atlanta is going to be in a much better position to attract outside institutional capital to build appropriate lab office space, because we're not going to have an overbuilt inventory,” Ross said.

November 4, 2026
CEO Note: A New Political Landscape, A Continued Commitment to Georgia Life Sciences Georgia's 2026 election results mark a historic shift in the state's political landscape, setting the stage for a new administration, new statewide leadership, and a potentially changed balance of power in the General Assembly as we approach the 2027 legislative session. At the national level, Democrats won control of both chambers of Congress , creating a new dynamic for federal policymaking. With the presidency remaining under Republican leadership, the coming years will require bipartisan cooperation to advance legislation. Changes in congressional leadership and committee oversight could significantly affect healthcare, federal research funding, FDA policy, drug pricing, and patient access. The most significant changes for our industry, however, are happening here in Georgia. Keisha Lance Bottoms' victory in the gubernatorial race marks a historic transition in state leadership, ending more than two decades of Republican control of the Governor's Office. She will also become the first Black woman elected governor in U.S. history. Democrats also swept Georgia's statewide executive offices , including lieutenant governor, attorney general, secretary of state, and the commissioners responsible for agriculture, labor, and insurance. These leadership changes create new opportunities for engagement on the policies and investments that shape Georgia's economy. In the General Assembly, Democrats made substantial gains and appear positioned to take control of the Georgia House of Representatives , pending final results in several close races. Republicans retained a narrowed majority in the State Senate. This potentially divided legislative environment will require thoughtful engagement and collaboration across party lines. We can also expect considerable turnover in the General Assembly, with dozens of new legislators beginning their terms in January. Along with a new Governor and incoming administration, this creates an important opportunity to introduce policymakers to Georgia's life sciences industry, its economic contributions, and its potential for future growth. What Does This Mean for Georgia's Life Sciences Industry? Life sciences is an economic development priority that should transcend party lines. Our industry's growth depends on a combination of sound public policy, private investment, research, workforce development, infrastructure, and a business environment that encourages innovation and commercialization. As Georgia establishes its new leadership priorities, several areas will be particularly important: Economic Development and Manufacturing: Positioning Georgia to attract and retain biopharmaceutical, biotechnology, and MedTech companies while advancing the infrastructure and capabilities needed to support scale-up manufacturing. Research and Commercialization: Strengthening connections between Georgia's research institutions, emerging companies, investors, and industry partners to move discoveries from the laboratory into commercial applications. Workforce Development: Expanding investment in technical education, apprenticeships, and industry-aligned training to prepare Georgians for the growing range of life sciences careers. Capital and Investment: Improving access to capital and supporting programs that help Georgia-based companies grow, commercialize technologies, and remain competitive. Healthcare Innovation and Patient Access: Supporting an environment that encourages medical innovation, advances research, and improves patient access to new treatments and technologies. These priorities align directly with Pathways & Partnerships: A Roadmap for Georgia's Life Sciences Sector , our ten-year strategy to position Georgia as a leading scale-up manufacturing hub in the Southeast. Georgia enters this transition with both an opportunity and a clear need to strengthen its competitiveness in life sciences. The recently released BIO/TEConomy report highlights the industry's significant contributions, including more than 42,600 jobs across over 4,200 establishments, while reinforcing the opportunity for Georgia to accelerate growth relative to other states. Our Roadmap provides a foundation for working with policymakers to turn these opportunities into sustained investment, stronger industry partnerships, and high-quality jobs throughout Georgia. GLS's Role Moving Forward For Georgia Life Sciences, this transition reinforces the importance of our role as the industry's statewide voice and convener. We will be intentional about building relationships with the incoming administration, new legislative leadership, returning legislators, and state agencies. We must ensure that policymakers understand not only the healthcare implications of our industry, but also its broader economic impact: high-quality jobs, significant research investment, advanced manufacturing, innovation, and opportunities for communities across Georgia. At the federal level, we will continue working with our national partners and Georgia's congressional delegation to advocate for policies that sustain research and innovation, support a predictable regulatory environment, strengthen American biomanufacturing, and advance patient access. With a new administration and many new legislators, we have an opportunity to establish a stronger understanding of what it takes to build and sustain a competitive life sciences ecosystem. That means bringing industry leaders to the table, communicating our priorities, identifying areas of bipartisan alignment, and advocating for policies that support long-term growth. Our industry's success requires a long-term commitment that extends beyond any election cycle or administration. The political landscape may change, but our commitment to advancing Georgia's life sciences industry remains constant. We look forward to working with leaders on both sides of the aisle to ensure Georgia continues to be a place where life sciences companies can innovate, invest, manufacture, and grow.
October 30, 2026
For Georgians living with serious and rare diseases, how quickly and predictably a new treatment moves through U.S. Food and Drug Administration (FDA) review can make a real difference. That predictability also matters to the researchers and businesses that make up Georgia’s growing life sciences sector. Both depend in large part on the Prescription Drug User Fee Act (PDUFA), a longstanding bipartisan program that Congress needs to reauthorize by 2027. How PDUFA Works Since 1992, PDUFA has allowed the FDA to collect user fees from biopharmaceutical companies to supplement the agency’s resources for reviewing new medicines. In exchange, the FDA commits to clear, predictable review timelines. The agency’s standards for safety and efficacy remain unchanged. By providing additional resources and establishing clear performance goals, PDUFA helps ensure patients can access new treatments in a more timely and predictable manner. The result of PDUFA have been significant. Before PDUFA, FDA reviews often took more than two years. Today, the median review time is 10 months for standard applications and 8 months for priority applications. In 2025, nearly 70% of new medicines were approved in the U.S. before any other country. What’s at Stake in 2027 Congress reauthorizes PDUFA every five years. The current agreement, PDUFA VII, expires September 30, 2027. Timely reauthorization is critical to maintaining the FDA’s review capacity, preserving regulatory predictability, and ensuring patients continue to benefit from medical innovation. Georgia stakeholders recently came together to talk through what that means here at home. On October 28, Georgia Life Sciences, the MTS Sickle Cell Foundation, and Georgia First hosted “PDUFA: How Medicines Reach People,” a lunch-and-learn at Brookhaven City Centre. Patient advocates, congressional staff, and business and academic leaders heard from Nick Magallanes of Todd Strategy Group, Natalie Crawford of Georgia First, Maria Thacker-Goethe of Georgia Life Sciences, and Mapillar Dahn of the MTS Sickle Cell Foundation. What We Heard At the event, speakers came at PDUFA from different angles, but the common thread was how the program affects Georgians. Mapillar Dahn of the MTS Sickle Cell Foundation stressed that patients need to remain at the center of conversations. As a mother of three daughters with Sickle Cell Disease, Mapillar stressed that she wants the FDA to have what it needs to carry out a thorough review without unnecessary delays. The confidence families place in a treatment depends in part on confidence in that process. Natalie Crawford with Georgia First and Mended Hearts spoke about the need for a fully resourced FDA so that Georgia patients have access to innovative treatments and also for a healthy Georgia economy. Additionally, Maria Thacker-Goethe spoke to what PDUFA reauthorization means for Georgia’s booming life sciences sector. She warned that without PDUFA reauthorization, research across the board will be stifled – ranging from devastating impacts to small startups to significant delays in investments and research. Part of a National Conversation As Congress prepares for the 2027 reauthorization, conversations like these help bring together patients, advocates, and community leaders to highlight the real-world importance of the program. Decisions made in this reauthorization cycle will shape FDA resources and review timelines nationwide. By reauthorizing PDUFA on time, Congress can make sure the FDA can keep reviewing new medicines efficiently and patients in Georgia and across the country can get the treatments they need. 
October 29, 2026
Increasingly high bond rates are having important implications for the U.S. life sciences ecosystem – and underscore the role of mergers and acquisitions (M&A) and other pro-competitive partnerships in advancing innovation. The upshot. Developing a new medicine requires significant and sustained investment over many years. This makes the life sciences industry especially sensitive to changes in the cost and availability of capital. With financial conditions tightening, a predictable environment for life sciences M&A is critical to sustaining investment in the next generation of cutting-edge treatments and cures. Why bond rates matter. It can cost billions and take more than a decade to bring a new treatment or cure to patients. Often, these companies operate without a profit and rely on outside investment (such as venture capital) to finance this high-stakes journey. When relatively low-risk investments like U.S. Treasury bonds offer stronger returns, investors need significantly greater potential returns to justify betting on riskier, long-term investments, such as drug development. The cost to early-stage life sciences investment. For emerging life sciences companies, less available capital can mean fewer resources to advance promising science and fewer new cures reaching patients. Research from NBER estimated that an unexpected one-percentage-point increase in interest rates reduces R&D spending across industries by approximately 1–3% and venture investment by roughly 25% over the following one to three years. M&A as an investment incentive. A healthy M&A environment provides a critical incentive for investors to support high-risk science by offering a potential exit. The prospect of an acquisition allows investors to realize returns from financing early-stage research – and reinvest that capital in the next generation of treatments and cures. M&A helps advance promising innovation. M&A is similarly vital to turning the promising science that attracted investment into approved medicines for patients. Emerging companies contribute specialized scientific knowledge and innovative drug candidates – but often depend on partnerships with larger, more established companies to access the clinical-development expertise, regulatory capabilities and infrastructure needed to bring medicines to patients. The evidence reinforces this complementary relationship. Findings from Cornerstone Research show that drug projects acquired from smaller companies by firms with prior launch experience were three times more likely to launch – and five times more likely to launch as novel drugs – than projects acquired by another small firm. A predictable pathway forward. When higher bond rates raise the bar for investing in innovation, policymakers should avoid adding unnecessary barriers to an already challenging investment environment. A predictable and balanced approach to merger enforcement can help preserve life sciences M&A as a vital pathway for transforming promising scientific discoveries into new medicines for patients. Source: Importance of Life Sciences M&A Amid Rising Interest Rates - Partnership for the U.S. Life Science Ecosystem (PULSE)
MORE POSTS